Peloton Therapeutics, Inc., is a clinical-stage biotechnology company that discovers and develops first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities.  Peloton Therapeutics’ lead program, PT2385, is a first-in-class small molecule targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of renal and other cancers.


Click above image for video discussing Peloton’s HIF-2a inhibitor.

Peloton Therapeutics Doses First Patient with Solid Tumors with Follow-On Hypoxia-Inducible Factor 2α (HIF-2α) Antagonist

December 15, 2016, 8:00 AM Central Standard Time

Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing novel small molecule cancer therapies, announced today dosing of the first patient with their follow-on small molecule drug targeting Hypoxia-Inducible Factor 2a (HIF-2a), PT2977. The clinical trial is designed to assess the safety and pharmacokinetics of PT2977 in patients with a variety of solid tumors.  For more information on the clinical trial of PT2977 visit